Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WRN | Q14191 | 1/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037645 | 1.00 | WRN (0.61) | WRNPIK3CDPIK3C2BPIK3CGGAA | |
| SCHEMBL25035210 | 0.97 | WRN (0.61) | WRNPIK3CDPIK3C2BPIK3CGGAA | |
| SCHEMBL30038429 | 0.94 | WRN (0.59) | WRNWDR5 | |
| SCHEMBL30984281 | 0.94 | WRN (0.62) | WRNPIK3CDPIK3C2BPIK3CGWDR5 | |
| SCHEMBL25036704 | 0.92 | WRN (0.57) | WRNPIK3CDPIK3C2BPIK3CGWDR5 | |
| SCHEMBL30038198 | 0.92 | WRN (0.57) | WRNPIK3CDPIK3C2BPIK3CGWDR5 | |
| SCHEMBL30038380 | 0.91 | WRN (0.59) | WRNWDR5 | |
| SCHEMBL25036830 | 0.90 | WRN (0.57) | WRN | |
| SCHEMBL30984186 | 0.90 | WRN (0.57) | WRNPIK3CDPIK3C2BPIK3CGGAA | |
| SCHEMBL30984208 | 0.90 | WRN (0.59) | WRNPIK3CDPIK3C2BPIK3CGWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | WRN 1829/4885PIK3CD 2890/4885PIK3C2B 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.